Markets | | |
Procter & Gamble stock (NYSE:PG) is up over 24% in 2019. One reason for investor optimism is that at several points this year, the stock has used a prior level of support to propel the stock to higher highs.
That same scenario seems to be playing out right now. After a post-earnings spike, PG... Read the Full Story |
|
From Our PartnersFormer Lehman Brothers executive reveals one of Wall Street's best kept secrets. A proven system for turning $1,000 into $1.3 Million (or more) -without touching the stock market.
In fact, this system is responsible for the most profitable investment of all time! | |
|
Markets | | | Shares of Foot Locker (NYSE: FL) were down almost 3% on Friday after the company reported third-quarter earnings. EPS beat estimates but revenue fell below where analysts were expecting. The miss here along with narrowing revenue guidance from management fed the bears and sent shares down.
The stoc... Read the Full Story |
|
Markets | | |
With the retail sector in turmoil following dismal earnings almost across the board in the sector this week, TJX Companies’ (NYSE: TJX) earnings report on Tuesday will be a breath of fresh air to investors.
As heads were still spinning from Kohls’ and Home Depot’s reports and th... Read the Full Story |
|
From Our Partners5 years from now, you'll probably wish you grabbed this stock... | | Click for more |
|
Markets | | |
The Conference Board released the Consumer Confidence numbers for November. The number came in at 125.5. The number did not meet analysts’ expectations for a 128.2 reading. The 125.5 number was the fourth straight month that the number declined and was the lower reading since the spring.
Th... Read the Full Story |
|
Stocks | | | The widely accepted belief that markets can’t be timed is typical conventional thinking. In reality, markets are timed every trading day by numerous algorithmic trading programs. Timing as it applies to forecasting and trading the direction and magnitude of a price move within a specific span ... Read the Full Story |
|
From Our PartnersSweeping new legalization could make investors wealthy. FREE Pot Stock Profit Calendar reveals key dates for investors. And it's yours FREE today. | | Click here to download it instantly... |
|
The Early Bird Stock Of The Day Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for patients treated with rivaroxaban or apixaban. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG, NMOSD, ALS, COVID-19, and HSCT-TMA; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1820 that is in Phase I clinical trial, a therapeutic antagonist of properdin; and ALXN1720, which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 that is in Phase III clinical trials for the treatment of Wilson disease; ALXN1830, which are in Phase I clinical trials for neonatal Fc receptor; ALXN2040 and ALXN2050 to treat diseases associated with dysregulation of the complement alternative pathway; ALXN1850, an enzyme replacement therapy; ALXN2060 for treating transthyretin amyloidosis; and ALXN2075 for treatment of relapsed/refractory chronic lymphocytic leukemia. The company serves distributors, pharmacies, hospital, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; and agreements with Dicerna Pharmaceuticals, Inc., Zealand Pharma A/S, Caelum Biosciences, Inc., Stealth BioTherapeutics Corp., and Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts. | | View Today's Stock Pick |
|
